1. Home
  2. STVN vs BBIO Comparison

STVN vs BBIO Comparison

Compare STVN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • BBIO
  • Stock Information
  • Founded
  • STVN 1949
  • BBIO 2015
  • Country
  • STVN Italy
  • BBIO United States
  • Employees
  • STVN N/A
  • BBIO N/A
  • Industry
  • STVN Containers/Packaging
  • BBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • STVN Consumer Discretionary
  • BBIO Health Care
  • Exchange
  • STVN Nasdaq
  • BBIO Nasdaq
  • Market Cap
  • STVN 6.2B
  • BBIO 5.6B
  • IPO Year
  • STVN 2021
  • BBIO 2019
  • Fundamental
  • Price
  • STVN $22.88
  • BBIO $33.79
  • Analyst Decision
  • STVN Buy
  • BBIO Strong Buy
  • Analyst Count
  • STVN 6
  • BBIO 13
  • Target Price
  • STVN $27.50
  • BBIO $48.33
  • AVG Volume (30 Days)
  • STVN 373.4K
  • BBIO 2.6M
  • Earning Date
  • STVN 03-06-2025
  • BBIO 02-20-2025
  • Dividend Yield
  • STVN 0.25%
  • BBIO N/A
  • EPS Growth
  • STVN N/A
  • BBIO N/A
  • EPS
  • STVN 0.48
  • BBIO N/A
  • Revenue
  • STVN $1,220,254,294.00
  • BBIO $217,765,000.00
  • Revenue This Year
  • STVN $3.01
  • BBIO $2,309.33
  • Revenue Next Year
  • STVN $7.07
  • BBIO N/A
  • P/E Ratio
  • STVN $48.10
  • BBIO N/A
  • Revenue Growth
  • STVN 3.53
  • BBIO 2209.77
  • 52 Week Low
  • STVN $16.56
  • BBIO $21.62
  • 52 Week High
  • STVN $34.73
  • BBIO $41.04
  • Technical
  • Relative Strength Index (RSI)
  • STVN 56.08
  • BBIO 68.27
  • Support Level
  • STVN $21.42
  • BBIO $33.73
  • Resistance Level
  • STVN $24.38
  • BBIO $36.24
  • Average True Range (ATR)
  • STVN 1.24
  • BBIO 1.55
  • MACD
  • STVN -0.08
  • BBIO 0.60
  • Stochastic Oscillator
  • STVN 59.95
  • BBIO 72.81

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: